SCHEMBL6160115

SCHEMBL6160115

O=C1CC(CSSCC2CC(=O)N(Cc3ccc(Oc4ccccc4)cc3)C2=O)C(=O)N1Cc1ccc(Oc2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 8/20 0.45
GAA P10253 3/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
HPGD P15428 1/20 0.45
CYP2C19 P33261 1/20 0.45
STAT6 P42226 1/20 0.45
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
MAPT P10636 2/20 0.44
MT-CO2 P00403 1/20 0.43
ALOX5 P09917 1/20 0.43
POLB P06746 2/20 0.43
USP2 O75604 1/20 0.43
PKM P14618 1/20 0.43
LMNA P02545 1/20 0.42
TSHR P16473 2/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6157032 0.82 ALDH1A1 (0.54) SMN1; SMN2ALDH1A1GAACYP1A2CYP3A4
SCHEMBL6164828 0.81 MT-CO2 (0.53) SMN1; SMN2ALDH1A1GAACYP1A2CYP3A4
SCHEMBL6157379 0.80 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1GAACYP1A2CYP3A4
SCHEMBL7082507 0.80 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1GAACYP1A2CYP3A4
SCHEMBL6159152 0.78 ALDH1A1 (0.50) SMN1; SMN2ALDH1A1GAACYP1A2CYP3A4
SCHEMBL6158988 0.78 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1GAACYP1A2CYP3A4
SCHEMBL6158601 0.76 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1GAACYP1A2CYP3A4
SCHEMBL6160031 0.75 HCRTR1 (0.49) SMN1; SMN2ALDH1A1GAACYP1A2CYP3A4
SCHEMBL6159751 0.75 HCRTR1 (0.52) SMN1; SMN2ALDH1A1GAACYP1A2CYP3A4
SCHEMBL6159504 0.75 HCRTR1 (0.49) SMN1; SMN2ALDH1A1GAACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6953789-B2 Thiol compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-10-11 US disclosed
US-20040157894-A1 Thiol compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-08-12 US disclosed
US-6699881-B2 MATRIX METALLOPROTEASE INHIBITORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-03-02 US disclosed
US-20030078253-A1 Thiol compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) 2003-04-24 US disclosed
US-6420415-B1 Thiol compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-07-16 US disclosed
EP-1132379-A1 NOVEL THIOL DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF Takeda Chemical Industries, Ltd. (JP) 2001-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078253-A1 Thiol compounds, their production and use TST, QSOX1, SULT1E1 SMN1; SMN2 3819/4885ALDH1A1 905/4885GAA 4878/4885
US-20040157894-A1 Thiol compounds, their production and use TST, SULT1E1, QSOX1 SMN1; SMN2 3509/4885ALDH1A1 877/4885GAA 4878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.